<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1119">
  <stage>Registered</stage>
  <submitdate>4/04/2006</submitdate>
  <approvaldate>4/04/2006</approvaldate>
  <nctid>NCT00311090</nctid>
  <trial_identification>
    <studytitle>Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs</studytitle>
    <scientifictitle>International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity</scientifictitle>
    <utrn />
    <trialacronym>EQUINOX</trialacronym>
    <secondaryid>2005-005326-30</secondaryid>
    <secondaryid>EFC5945</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Deep Venous Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Idrabiotaparinux sodium
Treatment: drugs - Idraparinux sodium
Treatment: drugs - Avidin
Treatment: drugs - Placebo (for Avidin)

Experimental: Idrabiotaparinux - Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.
In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)

Active Comparator: Idraparinux - Idraparinux sodium, 2.5 mg, once-weekly for 6 months
In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)


Treatment: drugs: Idrabiotaparinux sodium
0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection

Treatment: drugs: Idraparinux sodium
0.5 mL pre-filled syringe for 2.5 mg
Subcutaneous injection

Treatment: drugs: Avidin
100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes

Treatment: drugs: Placebo (for Avidin)
Avidin matching powder in 10 mg/mL solution
Intravenous infusion for 30 minutes

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bioequipotency sub-study: idrabiotaparinux/idraparinux ratio for pharmacodynamic exposure parameters</outcome>
      <timepoint>Day 183</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Avidin neutralizing effect substudy: decrease in anti-Xa activity between the start and end of the avidin infusion</outcome>
      <timepoint>Day 183 to Day 188</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile: idrabiotaparinux and idraparinux plasma concentrations</outcome>
      <timepoint>Days 15, 36, 57, 92 and 183</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: number of participants with clinically relevant bleedings and number of deaths as confirmed by a Central Independent Adjudication Committee (CIAC)</outcome>
      <timepoint>First 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: number of participants with symptomatic recurrent venous thromboembolism as confirmed by the CIAC</outcome>
      <timepoint>First 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Confirmed acute symptomatic DVT of the lower limbs</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled
             hypertension)

          -  Active bleeding or high risk for bleeding.

          -  Pregnancy or childbearing potential without proper contraceptive measures.

          -  Breastfeeding

          -  Known allergy to idraparinux, SSR126517E, or egg proteins

          -  Indication of prolonged anticoagulation for other reason than DVT of the lower limbs

          -  Symptomatic pulmonary embolism (PE)

          -  Life expectancy &lt; 6 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>757</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis - Macquarie Park</hospital>
    <postcode>NSW 2113 - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Natanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>New Zealand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The three purposes of this study are the following:

        -  To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux
           (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep
           venous thrombosis (DVT) and pulmonary embolism (PE), and bleeding risk;

        -  To compare the activities of idrabiotaparinux and idraparinux directly in blood during
           and after a 6-month treatment;

        -  To check the ability of avidin (SSR29261) to reverse the blood thinning activity of
           idrabiotaparinux at the end of a 6-month treatment period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00311090</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>